S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

NCT00085709 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

637

Enrollment

NETWORK

Sponsor class

Conditions

Leukemia

Interventions

DRUG: gemtuzumab ozogamicin
OTHER: observation
DRUG: Cytosine arabinoside
DRUG: Daunomycin

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]